Patents by Inventor Véronique Gire

Véronique Gire has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Delta133P53Beta and Delta133P53Gamma Isoforms Are Biomarkers of Cancer Stem Cells
    Publication number: 20210214691
    Abstract: The present invention is in the field of oncology, and more particularly of cancer stem cells. It relates to a method for producing cancer stem cells based on overexpression of ?133p53? isoform, ?133p53? isoform, or both ?133p53? and ?133p53? isoforms; a method for predicting the risk that treatment with a chemotherapeutic anti-cancer agent induces cancer stem cells in a subject suffering from cancer from a cancer sample of said subject, based on detection of an increase in ?133p53? isoform, ?133p53? isoform, or both ?133p53? and ?133p53? isoforms following chemotherapeutic anti-cancer treatment; to therapeutic uses of a combination of chemotherapeutic anti-cancer agent and an agent reducing ?133p53? isoform, ?133p53? isoform, or both ?133p53? and ?133p53? isoforms expression; and also to screening methods for anti-cancer stem cells agents.
    Type: Application
    Filed: February 3, 2021
    Publication date: July 15, 2021
    Inventors: Pierre Roux, Nikola Arsic, Gilles Gadea, Philippe Fort, Fanny Thomas, Véronique Gire
  • Delta133p53beta and delta133p53gamma isoforms are biomarkers of cancer stem cells
    Patent number: 10920198
    Abstract: The present invention is in the field of oncology, and more particularly of cancer stem cells. It relates to a method for producing cancer stem cells based on overexpression of ?133?536 isoform, ?133?53? isoform, or both ?133?536 and ?133?53? isoforms; a method for predicting the risk that treatment with a chemotherapeutic anti-cancer agent induces cancer stem cells in a subject suffering from cancer from a cancer sample of said subject, based on detection of an increase in ?133?536 isoform, ?133?53? isoform, or both ?133?536 and ?133?53? isoforms following chemotherapeutic anti-cancer treatment; to therapeutic uses of a combination of chemotherapeutic anti-cancer agent and an agent reducing ?133p536 isoform, ?133?53? isoform, or both ?133?536 and ?133?53? isoforms expression; and also to screening methods for anti-cancer stem cells agents.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: February 16, 2021
    Assignees: Centre National de la Recherche Scientifique (CNRS), Universite de Montpellier
    Inventors: Pierre Roux, Nikola Arsic, Gilles Gadea, Philippe Fort, Fanny Thomas, Véronique Gire